Théa and the manufacturer Excelvision, a subsidiary of the Fareva group, inaugurated a new sterile production unit in Annonay on 26 January 2017.

4000 m² and 2 production lines are to be used entirely for the manufacture and packaging of eye drops in aseptic conditions. These new facilities can accommodate up to 5 production lines.

With the deployment of these two BFS (Blow Fill Seal) lines, the production capacities of Excelvision single-dose preservative-free eye drops will be increased to 800 million units, compared with the 500 produced today.

This investment will consequently increase capacity for the manufacture and packaging of preservative-free eye drops developed by Théa Laboratories, particularly for the treatment of glaucoma. STARS : pour calculer le degré de risque d’un patient de développer une DMLA